EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites

Cuijiao Feng iD, Guangqi Gao, Qiuwen He, Lai-Yu Kwok, Cong Liu, Chang Li, Li Dong iD, Zhihong Sun iD, Heping Zhang iD

Science Advances · 2026

DOI: 10.1126/sciadv.aeg8202 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Science Advances, 2026. Verfasst von Cuijiao Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Hohhot, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Bifidobacterium animalis, Antigens, Neoplasm. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Earmarked fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gut dysbiosis drives therapeutic resistance, yet the relationships among typical tumor markers, gut microbiota, and treatment efficacy remain poorly defined. Here, elevated serum CYFRA 21-1 in advanced non–small cell lung cancer (NSCLC) correlates with gut dysbiosis, including Bifidobacterium animalis depletion and reduced immunomodulatory metabolites. Fecal supernatant from patients with high-CYFRA attenuated immunochemotherapy efficacy in tumor-bearing mice, linked to disrupted tryptophan and phenylalanine metabolism. Adjuvant B. animalis subsp. lactis V9 enhanced tumor control and antitumor immunity, coinciding with elevated quinaldic acid and catechol, metabolites associated with caspase-dependent apoptosis and ferroptosis. Cell-free fecal supernatant transferred antitumor effects, independent of bacterial colonization. In a randomized, double-blind, placebo-controlled pilot trial ( n = 30), adjunctive B. lactis V9 associated with a higher objective response rate (47% versus 33%), disease control rate (87% versus 67%), and prolonged progression-free survival in responders, who exhibited enriched B. animalis and elevated quinaldic acid/catechol (area under the curve = 0.73/0.82). These findings suggest CYFRA 21-1 may identify a modifiable, microbiome-linked state of treatment resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBifidobacterium animalisAntigens, NeoplasmKeratin-19Drug Resistance, NeoplasmHumansAnimalsMiceFemaleImmunotherapyMale

Substanzen

Antigens, NeoplasmKeratin-19antigen CYFRA21.1

Autor:innen und Institutionen

  • Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Hohhot, China.
  • Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Inner Mongolia Agricultural University, Hohhot, China.
  • Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, China.
  • Medical Oncology, Inner Mongolia People's Hospital, Hohhot, China.

ORCID-Profile: Cuijiao Feng, Li Dong, Zhihong Sun, Heping Zhang

Förderung

  • National Natural Science Foundation of China
  • Earmarked fund

Zitieren

APA

Feng, C., Gao, G., He, Q., Kwok, L. Y., Liu, C., Li, C., Dong, L., Sun, Z., & Zhang, H. (2026). Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites. Science Advances. https://doi.org/10.1126/sciadv.aeg8202

Vancouver

Feng C, Gao G, He Q, Kwok LY, Liu C, Li C, et al. Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites. Science Advances. 2026. doi:10.1126/sciadv.aeg8202

BibTeX
@article{Feng2026,
  author = {Feng, Cuijiao and Gao, Guangqi and He, Qiuwen and Kwok, Lai-Yu and Liu, Cong and Li, Chang and Dong, Li and Sun, Zhihong and Zhang, Heping},
  title = {Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via microbial metabolites},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aeg8202}
}
Kostenlos starten →